According to a recent research report issued by Mizuho, Sarepta Therapeutics (NASDAQ:SRPT) stock has had its “buy” rating reissued. Mizuho has set a price target of $160.00 for the biotechnology company’s stock, indicating a potential upside of 39.45% from its current price.
As of September 27, 2023, NASDAQ:SRPT opened at $114.74. Over the past year, the stock has seen a low of $100.15 and a high of $159.89. The company boasts a debt-to-equity ratio of 1.67, a current ratio of 4.96, and a quick ratio of 4.50. The 50-day simple moving average stands at $113.23 while the 200-day simple moving average is $122.75. With a market capitalization of $10.10 billion and a beta of 0.94, Sarepta Therapeutics continues to be an attractive option for investors.
Several hedge funds have recently adjusted their stakes in the company as well, with notable activity from Spire Wealth Management and First Horizon Advisors Inc., among others.
In terms of financial performance, Sarepta Therapeutics reported its quarterly earnings on August 2nd earlier this year. The results revealed an EPS (earnings per share) of ($0.27), surpassing analysts’ consensus estimates by $1.62 with significant improvement compared to the previous year’s quarter when it reported an EPS of ($2.65). Despite its negative net margin of 90.46% and negative return on equity of 91.22%, the company achieved revenue worth $261.20 million for the quarter, surpassing the consensus estimate by approximately $5 million.
Looking ahead, equities research analysts anticipate that Sarepta Therapeutics will post an EPS of -9.21 for the current year.
With these factors in mind, investors may find Sarepta Therapeutics to be an intriguing option, particularly considering the positive rating from Mizuho and the potential upside indicated by their price target. As always, investors should conduct thorough research and consider their own investment strategies before making any decisions.
[bs_slider_forecast ticker=”FBIN”]
Sarepta Therapeutics Receives Mixed Ratings from Analysts, Director Transactions Highlight Investor Interest
Sarepta Therapeutics, a renowned biotechnology company, has recently caught the attention of several brokerage firms and experts in the field. A research note published by StockNews.com on August 17th provided a comprehensive analysis of Sarepta Therapeutics and assigned the company a “hold” rating. Furthermore, Royal Bank of Canada expressed an optimistic outlook for Sarepta Therapeutics, increasing their target price from $221.00 to $223.00 and bestowing upon the stock an “outperform” rating on August 3rd.
This positive sentiment was not shared by all, as JPMorgan Chase & Co. lowered their target price from $217.00 to $213.00 in a report released on June 23rd, indicating a more conservative view towards the stock. Conversely, Bank of America had a more favorable perspective and raised their price target for Sarepta Therapeutics from $176.00 to $186.00 on June 23rd.
The praises for Sarepta Therapeutics did not stop there, as Needham & Company LLC reiterated its “buy” rating and established a price objective of $185.00 on August 3rd.
Overall, out of the numerous research analysts who evaluated the stock, two gave it a hold rating while fourteen others expressed strong confidence in Sarepta Therapeutics by issuing buy ratings.
To gain further insights into this promising investment opportunity, Bloomberg.com provides valuable data regarding Sarepta Therapeutics, endorsing it as a “Moderate Buy” with an average consensus price target set at $173.70.
In additional news that may pique investors’ interest, Director Michael Andrew Chambers executed a transaction on August 10th where he acquired an impressive number of shares totaling 34,867 in Sarepta Therapeutics. The average cost per share was reported at $106.15 resulting in an overall value of $3,701,132.05. Following this purchase, the director now holds a substantial shareholding of 213,331 shares valued at approximately $22,645,085.65.
This significant buy of Sarepta Therapeutics’ stock by Director Michael Andrew Chambers was disclosed in a legal filing with the Securities & Exchange Commission (SEC), available for further scrutiny through the provided link.
On that same day, another transaction occurred where Director Hans Lennart Rudolf Wigzell sold 15,000 shares of Sarepta Therapeutics’ stock at an average price of $106.72 per share. The total value amounted to $1,600,800.00. Following the completion of this sale, Director Wigzell now possesses 20,994 shares in the company which are estimated to be worth around $2,240,479.68. The details of this transaction were made public in a disclosure document filed with the SEC and can be accessed through the provided link.
It is also worth noting that insiders own approximately 7.40% of Sarepta Therapeutics’ stock.
These recent developments within Sarepta Therapeutics provide investors with invaluable information regarding both external and internal factors influencing the company’s performance and stock valuation in the market. As always, potential investors are advised to conduct thorough due diligence in order to make informed investment decisions.
